MLN 519

Drug Profile

MLN 519

Alternative Names: LDP 519; MLN519; PN 05; PS 519

Latest Information Update: 29 Jun 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Millennium Pharmaceuticals
  • Class Anti-inflammatories; Lactones
  • Mechanism of Action Immunomodulators; Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Inflammation; Reperfusion injury; Stroke

Most Recent Events

  • 31 May 2004 A preclinical study has been added to the Neurological pharmacodynamics section
  • 17 Dec 2003 Preclinical data from a media release have been added to the Neurological disorders pharmacodynamics section
  • 17 Mar 2003 PAION has terminated its licence for MLN 519 in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top